Moreover, AT-0174 was synergistic when combined with anti-PD1 therapy on significant reduction of tumor growth, enhanced infiltration of CD8+ T cells into the TME, and improved survival time in animal models of treatment-resistant NSCLC tumors. Here, CD8A is linked to neoplasm.